{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:14:16Z","timestamp":1791216856326,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T00:00:00Z","timestamp":1380240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0075280","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T22:54:42Z","timestamp":1380322482000},"page":"e75280","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":91,"title":["Protein Kinase CK2 Inhibition Down Modulates the NF-\u03baB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells"],"prefix":"10.1371","volume":"8","author":[{"given":"Sabrina","family":"Manni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Brancalion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mandato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Quotti","family":"Tubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Colpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Cappellesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Zaffino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Speranza Antonia","family":"Di Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cabrelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Gurrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,9,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"AF Kisselev","year":"2012","journal-title":"Chem Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"MS Raab","year":"2009","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"S Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.seminhematol.2009.02.003","article-title":"Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib","volume":"46","author":"CS Mitsiades","year":"2009","journal-title":"Semin Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From Bortezomib to Other Inhibitors of the Proteasome and Beyond","volume":"22","author":"D Buac","year":"2013","journal-title":"Curr Pharm Des"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11899-012-0141-2","article-title":"New proteasome inhibitors in myeloma","volume":"7","author":"P Lawasut","year":"2012","journal-title":"Current hematologic malignancy reports"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beha.2012.04.007","article-title":"Proteasome inhibitors in mantle cell lymphoma","volume":"25","author":"B Holkova","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/fon.12.23","article-title":"Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin&apos;s lymphoma","volume":"8","author":"JL Koprivnikar","year":"2012","journal-title":"Future Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"T Hideshima","year":"2002","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"T Hideshima","year":"2009","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"T Hideshima","year":"2003","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.leu.2404200","article-title":"Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo","volume":"20","author":"TA Navas","year":"2006","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"P Gomez-Bougie","year":"2007","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.febslet.2007.04.031","article-title":"Managing and exploiting stress in the antibody factory","volume":"581","author":"S Cenci","year":"2007","journal-title":"FEBS letters"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nri2359","article-title":"The endoplasmic reticulum stress response in immunity and autoimmunity","volume":"8","author":"DJ Todd","year":"2008","journal-title":"Nature reviews Immunology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"EA Obeng","year":"2006","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbapap.2009.07.018","article-title":"Addiction to protein kinase CK2: a common denominator of diverse cancer cells?","volume":"1804","author":"M Ruzzene","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.385","article-title":"Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways","volume":"26","author":"F Piazza","year":"2012","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ruzzene M, Pinna LA (2009) Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim Biophys Acta.","DOI":"10.1016\/j.bbapap.2009.07.018"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1196\/annals.1329.019","article-title":"Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target","volume":"1030","author":"Y Miyata","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1007\/s00018-009-9152-0","article-title":"Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery","volume":"66","author":"Y Miyata","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"ref22","first-page":"6770","article-title":"Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells","volume":"62","author":"R Romieu-Mourez","year":"2002","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1097-2765(03)00358-7","article-title":"CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response","volume":"12","author":"T Kato Jr","year":"2003","journal-title":"Mol Cell"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-5793(97)00399-2","article-title":"Regulation of the DNA binding of p53 by its interaction with protein kinase CK2","volume":"408","author":"A Prowald","year":"1997","journal-title":"FEBS Lett"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1038\/sj.onc.1208762","article-title":"The &apos;regulatory&apos; beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation","volume":"24","author":"M Bjorling-Poulsen","year":"2005","journal-title":"Oncogene"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","article-title":"Protein kinase CK2 phosphorylates and upregulates Akt\/PKB","volume":"12","author":"G Di Maira","year":"2005","journal-title":"Cell Death Differ"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cellsig.2010.08.014","article-title":"CK2 inhibition induces apoptosis via the ER stress response","volume":"23","author":"A Hessenauer","year":"2011","journal-title":"Cell Signal"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e40144","DOI":"10.1371\/journal.pone.0040144","article-title":"Inhibition of Casein Kinase 2 Modulates XBP1-GRP78 Arm of Unfolded Protein Responses in Cultured Glial Cells","volume":"7","author":"T Hosoi","year":"2012","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-11-1789","article-title":"Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response","volume":"18","author":"S Manni","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.cellsig.2012.05.006","article-title":"CK2 regulates ATF4 and CHOP transcription within the cellular stress response signalling pathway","volume":"24","author":"CC Schneider","year":"2012","journal-title":"Cell Signal"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2005-11-013672","article-title":"Multiple myeloma cell survival relies on high activity of protein kinase CK2","volume":"108","author":"FA Piazza","year":"2006","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1359-6349(10)72121-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: interim report from the phase 1 clinical trial","volume":"8","author":"CS Padgett","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"A Siddiqui-Jain","year":"2010","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/1471-2407-10-526","article-title":"Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death","volume":"10","author":"F Piazza","year":"2010","journal-title":"BMC cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"PR Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"E Hoster","year":"2008","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/labinvest.2012.129","article-title":"The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies","volume":"92","author":"A Fassina","year":"2012","journal-title":"Lab Invest"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jcp.2010.078253","article-title":"Programmed cell death 4 (PDCD4) expression during multistep Barrett&apos;s carcinogenesis","volume":"63","author":"M Fassan","year":"2010","journal-title":"J Clin Pathol"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Ferguson AD, Sheth PR, Basso AD, Paliwal S, Gray K, <etal>et al<\/etal>.. (2010) Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett.","DOI":"10.1016\/j.febslet.2010.11.019"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"G Roue","year":"2011","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2174\/156802611795589638","article-title":"ATP site-directed inhibitors of protein kinase CK2: an update","volume":"11","author":"S Sarno","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"32606","DOI":"10.1074\/jbc.272.51.32606","article-title":"Activation of nuclear transcription factor NF-kappaB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit","volume":"272","author":"TA Bird","year":"1997","journal-title":"J Biol Chem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"32592","DOI":"10.1074\/jbc.M001358200","article-title":"Tumor necrosis factor alpha-induced phosphorylation of RelA\/p65 on Ser529 is controlled by casein kinase II","volume":"275","author":"D Wang","year":"2000","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"R Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.1253","article-title":"Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours","volume":"199","author":"R Lai","year":"2003","journal-title":"J Pathol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/1042819031000097339","article-title":"Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation","volume":"44","author":"H Ishikawa","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5858\/2005-129-990-ASOTSP","article-title":"Activation status of the JAK\/STAT3 pathway in mantle cell lymphoma","volume":"129","author":"MA Yared","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","article-title":"Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells","volume":"120","author":"L Zhang","year":"2012","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molcel.2011.07.039","article-title":"Serine 403 phosphorylation of p62\/SQSTM1 regulates selective autophagic clearance of ubiquitylated proteins","volume":"44","author":"G Matsumoto","year":"2011","journal-title":"Mol Cell"},{"key":"ref50","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"T Mujtaba","year":"2011","journal-title":"Discovery medicine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1038\/sj.onc.1209742","article-title":"Serine-phosphorylated STAT1 is a prosurvival factor in Wilms&apos; tumor pathogenesis","volume":"25","author":"OA Timofeeva","year":"2006","journal-title":"Oncogene"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000258867.79411.96","article-title":"Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis","volume":"27","author":"EJ Harvey","year":"2007","journal-title":"Arter Thromb Vasc Biol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.cellsig.2010.06.012","article-title":"STAT1 activation regulates proliferation and differentiation of renal progenitors","volume":"22","author":"H Wang","year":"2010","journal-title":"Cell Signal"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-266320","article-title":"A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway","volume":"118","author":"Y Zheng","year":"2011","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/0008-5472.CAN-08-3858","article-title":"Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy","volume":"69","author":"DM Schewe","year":"2009","journal-title":"Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0075280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T02:04:52Z","timestamp":1646618692000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0075280"}},"subtitle":[],"editor":[{"given":"Kristy L.","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,27]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0075280","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,27]]}}}